BIOPHTA
Created in 2020
Trend leader (A+)
Existing signals make this entity one of the most dynamic startupsSocial networks
2,437Activities
Technologies
Entity types
Location
8 Rue Maria Helena Vieira da Silva, 75014 Paris, France
Paris
France
Employees
Scale: 2-10
Estimated: 10
Engaged corporates
9
0 0Added in Motherbase
10 months, 2 weeks ago
Value proposition
Changing the lives of patients suffering from chronic eye diseases !
World Health Organization evaluates between 200 and 300 million, the number of people who are visually impaired by diseases against which pharmaceutical treatments are however existing. Many of these conditions have in common to cause permanent vision loss if they are not treated consistently.
The lack of adherence to prescription eye drops is the #1 Unmet Medical need in Ophthalmology. Poor treatment Compliance and Adhesion leads to a worse progression of Eye Diseases. BIOPHTA wants to change the lives of patients suffering from chronic eye diseases by creating a best-in-class solution to reduce the burden of treatments.
We develop a new way of treating the eye, with a novel pharmaceutical platform enabling a continuous Drug Delivery.
Our topical Mucoadhesive Ocular Hydrogel Insert releases drugs on the eye for a one-week period, causing higher efficacy & potency for medications. These Ocular Inserts will help patients to improve their adherence to treatment regimens. It also permits a better yield of the drugs by diminishing the frequency and complexity of eye drops application while generating a continuous and controlled sustained release.
BIOPHTA non-invasive topical ocular inserts are aimed at several ophthalmic indications by allowing better long-term control of diseases.
ophthalmology, drug development, drug delivery platform, biotechnology, retina, glaucoma, macular edema, and biopolymersOriginal language
Transformer l'ophtalmologie en soulageant les patients du fardeau du traitement de leurs maladies oculaires.
BIOPHTA est une société start-up Biotech visant à transformer l'ophtalmologie en soulageant les patients du fardeau lié à leurs pathologies oculaires.
L'Organisation mondiale de la santé évalue entre 200 et 300 millions les personnes atteintes de déficience visuelle causée par des maladies contre lesquelles des traitements pharmaceutiques existent pourtant. Beaucoup de ces maladies ont en commun de provoquer une perte de vision définitive si elles ne sont pas traitées correctement. À titre d'exemple, moins du tiers des patients atteints de glaucome suivent correctement leur prescription de collyre, conduisant pour la plupart des patients à une évolution irréversible de la maladie.
Bioadhesive Ophthalmics vise à transformer l'ophtalmologie en soulageant les patients du fardeau de leurs maladies oculaires. Notre objectif est de changer radicalement la façon de traiter l'œil avec une nouvelle plate-forme pharmaceutique pour l'administration de médicaments à l'œil.
Nous développons un insert oculaire mucoadhésif topique d'hydrogel qui libère des médicaments sur l'œil au cours d’une période d'une semaine, permettant ainsi aux traitements d’être plus efficaces et plus puissants. Notre insert oculaire topique aide les patients à améliorer leur observance des schémas thérapeutiques. Il permet également un meilleur rendement des médicaments en diminuant fréquence et complexité de l'application tout en permettant une libération prolongée continue et contrôlée.
Biophta – New Standard of Care for Eye Diseases
https://www.biophta.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 LCL Bank, Banking | LCL Bank, Banking | Other 3 Apr 2025 | | |
 | PariSanté Campus | Other 26 Mar 2025 | | |
 La French Tech Saint-Nazaire La Baule Pornic French Tech, Software Development | La French Tech Saint-Nazaire La Baule Pornic French Tech, Software Development | Other 7 Dec 2024 | | |
 EU-Startups Media, Software Development | EU-Startups Media, Software Development | Other 29 Aug 2024 | | |
 Atlanpole Biotherapies Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Atlanpole Biotherapies Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 18 Jul 2024 | | |
 Linkera Consulting, Information Services | Linkera Consulting, Information Services | Other 12 Jun 2024 | | |
 | HTL Biotechnology | Other 4 Jun 2024 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 31 Mar 2024 | | |
 Elaia Startup accelerator & VC, Venture Capital and Private Equity Principals | Elaia Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 3 Feb 2025 | | |